Answers are grounded in this paper and cite their sources.
OBJECTIVE: The objective of this study was to review and synthesize the mechanistic rationale and emerging clinical evidence for the use of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) in psychotic disorders. METHODS: The authors conducted a systematic review of the clinical literature relevant to GLP-1RA use in people with psychotic disorders. Searches of PubMed/MEDLINE, Embase, APA PsycInfo, and Cochrane CENTRAL were conducted from database inception through March 7, 2026, and were supplemented by searches of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform and reference-list screening. The findings were integrated into a narrative synthesis of preclinical and translational evidence relevant to novel metabolic mechanisms in the pathophysiology of psychotic disorders. RESULTS: Preclinical and early human mechanistic studies suggest that GLP-1RAs may influence several pathways relevant to psychotic disorders, including systemic and central glucose homeostasis, gut-brain signaling, inflammatory processes, redox alterations, mitochondrial function, and reward-related signaling. Clinically, the clearest evidence of benefit is for antipsychotic-associated weight gain and cardiometabolic risk, with most randomized clinical trials reporting meaningful improvements in body weight and metabolic outcomes. Relevant to comorbidities in psychotic disorders, the evidence for GLP-1RA effects on alcohol and nicotine use is suggestive but inconclusive. Available studies have not yet demonstrated consistent improvements in psychotic symptoms, cognition, or functioning. Limitations to the clinical evidence include small samples; short follow-up; heterogeneity in agents, dosing, and endpoints; and minimal incorporation of mechanistic endpoints. CONCLUSIONS: GLP-1RAs represent a clinically and mechanistically grounded strategy to address the substantial cardiometabolic burden in psychotic disorders, with the potential for reduced substance use and other neuropsychiatric benefits.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: